Nano Retina Inc.
Artificial retina for degenerative ophthalmic diseases
This article was originally published in Start Up
Executive Summary
Israel’s Nano Retina Inc. is developing an artificial retina that it hopes will provide a superior solution for restoring sight to patients with late-stage AMD and other degenerative ophthalmic diseases, who currently have no curative options. Its permanently implantable device is powered by an eye-safe laser that can be imbedded or attached to eyeglasses.
You may also be interested in...
Artificial Retinal Devices Help The Blind To See
Worldwide rates of all diseases that cause blindness are expected to double by 2020 due to the aging population, making this an area ripe for medical device innovation. A multibillion-dollar market has been built around the surgical correction of "front of the eye" age-related vision disorders such as presbyopia, but the technological evolution in ophthalmology has now reached the back of the eye. Artificial retinal prostheses are an increasingly popular area of investigation. Start-ups hoping to enter this market face daunting R&D, clinical and regulatory hurdles, and will require significant resources. We profile three such companies in this issue: 2C Tech Corp., LambdaVision and Nano Retina.
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.